evipedia.ai
← Back

UV Blood Irradiation for Health & Longevity

Created on 10/30/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

UV blood irradiation is a procedure that exposes a small share of a person's own blood to ultraviolet light and returns it to the body, sold mainly by wellness clinics to strengthen immunity. No study has tested it in healthy people pursuing long-term health; in small infection trials, adding it to antibiotics appeared to speed recovery. Risks come mainly from the procedure: bruising, fainting, bleeding and infection from reused equipment. (Full Review)

Protocol

Extracorporeal Knott method (UVC)
About 3.5 mL/kg
5–7% of blood volume, treated with citrate to prevent clotting, exposed for about 10 seconds at 253.7 nm, reinfused immediately; no protocol tested for healthy adults seeking longevity
Session spacing
One to three sessions per week
Common clinic practice for a short course; no comparison of schedules exists
Trial regimen
15 sessions over 22 weeks
AVIcure Hemo-modulator, a modified Knott device, in the hepatitis C trial
Time to effect
Acute infection
Minutes to days
Changes described in historical reports
Hepatitis C viral load
About 8–9 months
Low point after starting, in the hepatitis C trial
Lymphocyte effects
48–72 hours
Laboratory effects on immune white cells

Benefits

Contraindications
  • History of heparin-induced thrombocytopenia, or heparin or pork hypersensitivity (when heparin is used)
  • Use in place of established treatment for curable cancer or serious infection
  • Systemic lupus erythematosus
  • Porphyria (inferred; no human UVBI data)
  • G6PD deficiency (inferred; no human UVBI data)
  • Pregnancy (inferred; no human UVBI data)
  • Severe anemia or active bleeding disorders (inferred; no human UVBI data)
    •
Key Interactions
  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, clopidogrel): may induce bleeding with procedural heparin
  • Over-the-counter antiplatelet analgesics (aspirin, ibuprofen, naproxen): additive bleeding at the access site
  • Psoralens (methoxsalen): immune-suppressing damage to immune white cells from UVA devices
    •
Theoretical (inferred from mechanism)
  • Photosensitizing drugs (doxycycline, amiodarone, fenofibrate): light-triggered red cell breakdown
  • Photosensitizing supplements (St. John's wort): added risk of light-triggered damage
  • High-dose antioxidant supplements (vitamin C, vitamin E): blunting of the proposed oxidative signal
  • Bleeding-prone supplements (fish oil, ginkgo, high-dose vitamin E): bruising
  • Immunosuppressive drugs (tacrolimus, cyclosporine, prednisone): unpredictable immune suppression
  • Ozone blood treatment or high-dose intravenous vitamin C in the same session: red cell breakdown or oxygen-carrying failure of hemoglobin
    •

Risk & Side Effects

  • High:
  • Medium: Bloodborne infection from unsafe blood handling
    •
  • Low: Venipuncture reactions: bruising, fainting and vein inflammation; delayed effective treatment of serious disease; heparin-related bleeding and heparin-induced thrombocytopenia; flare of systemic lupus erythematosus
    •
  • Speculative: Oxidative damage to blood proteins, lipids and lymphocytes
    •

Monitoring

Marker Target Why
Platelet count 150–450 × 10⁹/L A fall signals heparin-induced thrombocytopenia
Hemoglobin Men 13.5–17.5 g/dL; women 12.0–15.5 g/dL Anemia limits repeated draws
Hepatitis B and C and HIV serology Negative Documents status before and after blood handling
HCV RNA (viral load) No established target for UVBI; track change from own baseline Expected to change when treating hepatitis C
ALT and AST ALT about 7–56 U/L, AST about 10–40 U/L Expected to change when treating hepatitis C

Cadence: Baseline before a first course; platelet count before each session in the first two weeks of any course using heparin, then monthly during continued sessions; complete blood count every 3 months of regular use; viral screening repeated 3–6 months after a course; disease-specific markers at 3 and 6 months.

Qualitative Assessment

  • Bruising, pain or redness at the access site after each session
  • Lightheadedness or fainting during or after the draw
  • Frequency and duration of infections over the following months
  • Energy levels and exercise tolerance compared with the pre-course baseline
  • Any skin rash or sun sensitivity, especially with photosensitizing medications
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.